A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Sanofi’s shares traded 0.2% lower on Monday morning in Paris. The stock has risen about 2% over the past 12 months. Despite the commitments it faces in France, CD&R has been drawn to the Sanofi ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

The new entity focuses on the discovery, design and development of RLTs. Credit: PeopleImages.com – Yuri A/Shutterstock. Sanofi and Orano Group subsidiary Orano Med have announced a partnership to ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

The buyout firm improves its bid by about €200 million CD&R still aims to sign a deal as soon as the coming days PAI Partners has submitted an improved offer for Sanofi ’s consumer health business, ...

A consortium including French private equity firm PAI Partners has raised its offer for Sanofi's consumer health business, Opella, according to sources. The group has revised its bid by €200m ...